Come up with a name for your new list and we'll add to it:
Vivaldi Biosciences raised a round of funding on May 16, 2007. Investors include
Bay City Capital.
Developing genetically modified vaccines to protect against common seasonal influenza and emergent pandemic influenza. Formed to commercialize patented vaccine and virus technologies developed at the…